Industry
MicrobiomePost discussed with Claire Derlot, Head of Programs at Biose Industrie, the GMP challenges when you have to go from bacteria to a drug.
Rebyota is the first and only FDA-approved Microbiome-Based Treatment for the prevention of recurrence of C. diff infection in adults.
Chicago-based company said it invested more than $30 million to help meet rising global demand
MicrobiomePost talked with Isabelle de Cremoux, CEO of Seventure Partners, about the news that will emerge in 2023.
Consumers would like to be more informed on the labelling and in communications about probiotic food, and about probiotic microorganisms in food and food supplements.
Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic microbiome-based therapy
Leigh Frame, Director, Integrative Medicine, GW School of Medicine & Health Sciences in Washington, discussed how to exploit metabolomic and genomic data to identify diet-specific signatures.
According to Christoph Lacroix (ETH Zurich), bifidobacteria are critical in the development of the neonatal microbiota. Here's why.
Savita Bernal, Chief Business Officer at MaaT Pharma, discussed the Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement.
Christine Moissl-Eichinger (Medical University of Graz, Austria) explains the changes in the microbiome of astronauts.
